Genetic and Protein Network Underlying the Convergence of Rett-Syndrome-like (RTT-L) Phenotype in Neurodevelopmental Disorders

Cells. 2023 May 21;12(10):1437. doi: 10.3390/cells12101437.

Abstract

Mutations of the X-linked gene encoding methyl-CpG-binding protein 2 (MECP2) cause classical forms of Rett syndrome (RTT) in girls. A subset of patients who are recognized to have an overlapping neurological phenotype with RTT but are lacking a mutation in a gene that causes classical or atypical RTT can be described as having a 'Rett-syndrome-like phenotype (RTT-L). Here, we report eight patients from our cohort diagnosed as having RTT-L who carry mutations in genes unrelated to RTT. We annotated the list of genes associated with RTT-L from our patient cohort, considered them in the light of peer-reviewed articles on the genetics of RTT-L, and constructed an integrated protein-protein interaction network (PPIN) consisting of 2871 interactions connecting 2192 neighboring proteins among RTT- and RTT-L-associated genes. Functional enrichment analysis of RTT and RTT-L genes identified a number of intuitive biological processes. We also identified transcription factors (TFs) whose binding sites are common across the set of RTT and RTT-L genes and appear as important regulatory motifs for them. Investigation of the most significant over-represented pathway analysis suggests that HDAC1 and CHD4 likely play a central role in the interactome between RTT and RTT-L genes.

Keywords: Rett syndrome; Rett-syndrome-like phenotype; atypical RTT syndrome; methyl-CpG-binding protein 2; neurodevelopmental disorders; overlapping phenotype; protein–protein interaction network.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Methyl-CpG-Binding Protein 2 / genetics
  • Mutation / genetics
  • Neurodevelopmental Disorders*
  • Phenotype
  • Rett Syndrome* / genetics
  • Transcription Factors / genetics

Substances

  • Methyl-CpG-Binding Protein 2
  • Transcription Factors

Grants and funding

This research was supported by private donors of TGen’s Center for Rare Childhood Disorders (C4RCD) through the TGen Foundation.